Ratings by Citi (Brendan Digan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/30/2026 | Stevanato Group S.p.A. | STVN | New Coverage | Buy (N/A) |
20.41 (19.49) |
-4.51% | Details | |
| 7/30/2026 | Sotera Health | SHC | New Coverage | Buy (N/A) |
17.53 (18.10) |
3.25% | Details | |
| 7/30/2026 | Qiagen NV | QGEN | New Coverage | Neutral (N/A) |
41.81 (50.39) |
20.52% | Details | |
| 7/30/2026 | Natera | NTRA | New Coverage | Buy (N/A) |
253.82 (403.95) |
59.15% | Details | |
| 7/30/2026 | ICON plc | ICLR | New Coverage | Neutral (N/A) |
178.18 (185.27) |
3.98% | Details | |
| 7/30/2026 | Guardant Health | GH | New Coverage | Buy (N/A) |
144.07 (169.08) |
17.36% | Details | |
| 7/30/2026 | Fortrea | FTRE | New Coverage | Buy (N/A) |
20.40 (23.63) |
15.83% | Details | |
| 7/30/2026 | Caris Life Sciences Inc | CAI | New Coverage | Buy (N/A) |
15.59 (32.00) |
105.26% | Details | |
| 7/30/2026 | Bruker | BRKR | New Coverage | Neutral (N/A) |
61.74 (57.59) |
-6.72% | Details | |
| 7/30/2026 | 10X Genomics | TXG | New Coverage | Neutral (N/A) |
46.32 (71.55) |
54.47% | Details |
